SOPHiA GENETICS Expands Partnership With AstraZeneca To Optimize Outcomes For Breast Cancer Patients

(RTTNews) - SOPHiA GENETICS SA (SOPH), Tuesday announced an expansion of collaboration with AstraZeneca (AZN), expecting to leverage its multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer.

Moreover, it will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer.

The expanded partnership is expected to position SOPHiA as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence.

In the pre-market hours, SOPH is moving down 4.5 percent, to $3.15 on the Nasdaq.